|
|
|
|
| LEADER |
04764nma a2201153 u 4500 |
| 001 |
EB002048376 |
| 003 |
EBX01000000000000001192042 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a books978-3-0365-1683-7
|
| 020 |
|
|
|a 9783036516837
|
| 020 |
|
|
|a 9783036516844
|
| 100 |
1 |
|
|a Badie, Christophe
|
| 245 |
0 |
0 |
|a Radiation Response Biomarkers for Individualised Cancer Treatments
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2021
|
| 300 |
|
|
|a 1 electronic resource (231 p.)
|
| 653 |
|
|
|a radiotherapy
|
| 653 |
|
|
|a machine learning
|
| 653 |
|
|
|a predictive tests
|
| 653 |
|
|
|a STING
|
| 653 |
|
|
|a gamma H2AX foci assay
|
| 653 |
|
|
|a genotoxicity tests
|
| 653 |
|
|
|a methods
|
| 653 |
|
|
|a cGAS
|
| 653 |
|
|
|a carbon-ion radiotherapy
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a protein
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a radiation-induced lung fibrosis
|
| 653 |
|
|
|a circulating tumour cells
|
| 653 |
|
|
|a exosomes
|
| 653 |
|
|
|a RILI
|
| 653 |
|
|
|a radiotherapy monitoring
|
| 653 |
|
|
|a radiation
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a immune infiltrate
|
| 653 |
|
|
|a individual radiosensitivity
|
| 653 |
|
|
|a late effects
|
| 653 |
|
|
|a relative biological effectiveness
|
| 653 |
|
|
|a pneumonitis
|
| 653 |
|
|
|a biodosimetry
|
| 653 |
|
|
|a plating
|
| 653 |
|
|
|a serum
|
| 653 |
|
|
|a human blood
|
| 653 |
|
|
|a microRNAs
|
| 653 |
|
|
|a tumour microenvironment
|
| 653 |
|
|
|a immunotherapy
|
| 653 |
|
|
|a telomeres
|
| 653 |
|
|
|a radiosensitivity
|
| 653 |
|
|
|a radiation-induced lung injury
|
| 653 |
|
|
|a liquid biopsy
|
| 653 |
|
|
|a circulating biomarkers
|
| 653 |
|
|
|a RILF
|
| 653 |
|
|
|a PBMCS
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a normal tissue
|
| 653 |
|
|
|a chromosomal instability
|
| 653 |
|
|
|a dicentric assay
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a inversions
|
| 653 |
|
|
|a abscopal effect
|
| 653 |
|
|
|a ionizing radiation
|
| 653 |
|
|
|a personalized medicine
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a uterine cervical cancer
|
| 653 |
|
|
|a clonogenic assays
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a proteomics
|
| 653 |
|
|
|a lung cancer
|
| 653 |
|
|
|a extracellular vesicles
|
| 653 |
|
|
|a normal tissue toxicity
|
| 653 |
|
|
|a head-and-neck tumors
|
| 653 |
|
|
|a IMRT
|
| 653 |
|
|
|a health surveillance analyses
|
| 653 |
|
|
|a squamous cell carcinoma
|
| 653 |
|
|
|a stroma
|
| 653 |
|
|
|a micronuclei
|
| 653 |
|
|
|a biological dosimetry
|
| 653 |
|
|
|a head and neck cancer
|
| 653 |
|
|
|a micronucleus assay
|
| 653 |
|
|
|a immune system
|
| 653 |
|
|
|a GC/MS
|
| 653 |
|
|
|a microRNA
|
| 653 |
|
|
|a metabolomics
|
| 653 |
|
|
|a chromosome aberrations
|
| 700 |
1 |
|
|a Rutten, Eric Andreas
|
| 700 |
1 |
|
|a Badie, Christophe
|
| 700 |
1 |
|
|a Rutten, Eric Andreas
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-1683-7
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/4079
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/76632
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 363
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a Personalised medicine is the next step in healthcare, especially when applied to genetically diverse diseases such as cancers. Naturally, a host of methods need to evolve alongside this, in order to allow the practice and implementation of individual treatment regimens. One of the major tasks for the development of personalised treatment of cancer is the identification and validation of a comprehensive, robust, and reliable panel of biomarkers that guide the clinicians to provide the best treatment to patients. This is indeed important with regards to radiotherapy; not only do biomarkers allow for the assessment of treatability, tumour response, and the radiosensitivity of healthy tissue of the treated patient. Furthermore, biomarkers should allow for the evaluation of the risks of developing adverse late effects as a result of radiotherapy such as second cancers and non-cancer effects, for example cardiovascular injury and cataract formation. Knowledge of all of these factors would allow for the development of a tailored radiation therapy regime. This Special Issue of the Journal of Personalised Medicine covers the topic of Radiation Response Biomarkers in the context of individualised cancer treatments, and offers an insight into some of the further evolution of radiation response biomarkers, their usefulness in guiding clinicians, and their application in radiation therapy.
|